Find the buyers most likely to be in.
Set a target profile and get the strategic and financial buyers most likely to be relevant, ranked from verified European deal history. Deterministic scoring with published weights, defensible in a kickoff meeting. How the score works
Start from a company
Type any company, covered or not. We read its public footprint and pre-fill the profile.
Company name or website · covered or not, we pre-fill sector and country from its public footprint
Or build the profile yourself
Sector
The target's industry family
Sub-sector
Optional precision within the family
Country
Where the company operates from · 16 European markets
Target size (EV)
Optional · adds a check-size fit against each fund
Sector match
Strict keeps only buyers with in-sector deals · Broad admits neighbouring sectors
Geography match
Strict requires deals in the country itself · Broad counts the rest of Europe
Target: NBE Therapeutics · Biotech · Switzerland · scored as Biotech · Switzerland, edit the profile above
How companies like this sold · 44 verified exits: 11% to sponsors, 73% to corporates and platforms, 14% via IPO, 2% other routes.
Route shift since 2020: sponsors 23% (was 30%), corporates and platforms 67% (was 54%), IPO 8% (was 15%) (sector-wide).
Recent deals in this marketAFINUM Management GmbH closed Fairbanks (2026) · Alantra Private Equity Healthcare Continuation Fund closed Deudafix (2026) · Apheon closed Alma (2026) · Apheon TMC HDC Long Term Value Fund (HarbourVest-led) + LFPI closed Alma (2026) · Apheon TMC HDC Long Term Value Fund SCSp (HarbourVest + LFPI-backed continuation fund) closed Alma (2026)
10 of the top 10 closed a deal in this space in the last 12 months.
Likely buyers · Biotech in Switzerland.
Memo view · print-readyRanked by fit on sector, geography, recency, current exposure and timing. Strength labels and tiers are published thresholds, not editorial picks.
Financial buyers 9
| # | Buyer | Match | ||||
|---|---|---|---|---|---|---|
| Tier 1 · Very High · score 70+ | ||||||
| 1 | Novo Holdings | 83Very High | ||||
| 2 | Archimedes Partners | 82Very High | ||||
| 4 | NORD Holding | 81Very High | ||||
| 5 | Bpifrance InvestissementGeographic expansion buyer | 80Very High | ||||
| 6 | ArchiMed | 80Very High | ||||
| 7 | ARCHIMED and Institut Mérieux | 80Very High | ||||
| 8 | ArchiMed and Tethys Invest | 80Very High | ||||
| 9 | Merieux Equity Partners / Vitruvian Partners | 79Very High | ||||
| 10 | NORD Holding / Pinova Capital | 79Very High | ||||
Strategic buyers 1
| # | Buyer | Match | ||||
|---|---|---|---|---|---|---|
| Tier 1 · Very High · score 70+ | ||||||
| 3 | Gilead SciencesGeographic expansion buyer | 82Very High | ||||
The full shortlist is open, precedents included. Pro adds the working tools.
Export the tiered buyer list to Excel, precedents and timing in the cells · Sourced press links on census add-on deals · Custom scoring weights